Gene

EMSY

EMSY transcriptional repressor, BRCA2 interacting

Explore in graph →CI-GENE-00044723HGNC:18071 ENSG00000158636 NCBI 56946 CIViC Approved

Curated evidence

Clinical evidence (2)

CIViC items involving this gene, grouped by molecular profile and therapy, with native levels and directions. 50 items per page.

civicCuratedShowing 1–2 of 2 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
EMSY Amplification1
Talazoparib	Acral Lentiginous Melanoma	Predictive	C	Supports Sensitivity Response	2	submitted	EID12148 An 88-year-old male acral melanoma patient harbouring EMSY gene amplification without abnormal BRCA2 expression levels was treated with PARPi, talazoparib. The patient was treated with talazoparib at … (full text at CIViC) PMID 38778889 · Nassief et al., 2024 · Open in CIViC	civic
EMSY Overexpression1
Bevacizumab + Carboplatin + PaclitaxelCombination	Ovarian Serous AdenocarcinomaALIAS	Predictive	B	Supports Sensitivity Response	3	submitted

Cohorts

Alteration frequency by cohort (9)

Frequency = cases affected / cases profiled within one cohort. Cohorts are never pooled.

cbioportalObserved9 cohort rows · frequency = affected / profiled, as published by each cohort; cohorts are not pooled. Hover a row badge for its release.

Cohort	Mapped cancer	Alteration	Affected (n)	Profiled (n)	Frequency (%)	Rank in cohort	Source
Squamous Cell Carcinoma of the Vulva (CUK, Exp Mol Med 2018) vsc_cuk_2018	Vaginal Squamous Cell Carcinoma, Not Otherwise Specified	Ssm

Literature

Linked publications (0)

Data not yet available

No publication linked to this gene yet.